Business Description
ArriVent BioPharma Inc
NAICS : 541714
SIC : 2834
ISIN : US04272N1028
Description
ArriVent BioPharma Inc is a clinical stage biopharmaceutical company dedicated to the identification, development and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize team's deep drug development experience to maximize the potential of lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 474.41 | |||||
| Equity-to-Asset | -0.94 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | N/A/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Future 3-5Y EPS without NRI Growth Rate | -13.97 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 69.92 | |||||
| 9-Day RSI | 55.94 | |||||
| 14-Day RSI | 53.17 | |||||
| 6-1 Month Momentum % | 66.24 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 13.76 | |||||
| Quick Ratio | 13.76 | |||||
| Cash Ratio | 12.94 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Shareholder Yield % | -18.44 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -231.05 | |||||
| ROA % | -35.4 | |||||
| ROIC % | -1838.32 | |||||
| ROC (Joel Greenblatt) % | -13126.19 | |||||
| ROCE % | -43.01 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| EV-to-EBIT | -9.17 | |||||
| EV-to-Forward-EBIT | -5.98 | |||||
| EV-to-EBITDA | -9.17 | |||||
| EV-to-FCF | -12.46 | |||||
| Earnings Yield (Greenblatt) % | -10.91 | |||||
| FCF Yield % | -6.83 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:AVBP
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
ArriVent BioPharma Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -2.623 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 53.17 | ||
| 14-Day ATR ($) | 1.674362 | ||
| 20-Day SMA ($) | 30.234 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range ($) | 14.35 - 36.37 | ||
| Shares Outstanding (Mil) | 33.7 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
ArriVent BioPharma Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
ArriVent BioPharma Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
ArriVent BioPharma Inc Frequently Asked Questions
What is ArriVent BioPharma Inc(AVBP)'s stock price today?
The current price of AVBP is $29.96. The 52 week high of AVBP is $36.37 and 52 week low is $14.35.
When is next earnings date of ArriVent BioPharma Inc(AVBP)?
The next earnings date of ArriVent BioPharma Inc(AVBP) is 2025-02-28 Est..
Does ArriVent BioPharma Inc(AVBP) pay dividends? If so, how much?
ArriVent BioPharma Inc(AVBP) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers